medicalxpress.com
·
Aug 31
Sustained reductions in inflammatory markers seen with novel antibody drug
The interleukin-6 (IL-6) antibody pacibekitug produced sustained reductions in inflammatory biomarkers in patients with chronic kidney disease at high inflammatory risk, according to results from the Phase II TRANQUILITY trial presented in a Hot Line session at ESC Congress 2026.
